Botti R E, Triscari J, Pan H Y, Zayat J
Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000.
Clin Neuropharmacol. 1991 Jun;14(3):256-61. doi: 10.1097/00002826-199106000-00010.
The capability of pravastatin and lovastatin, HMG-CoA reductase inhibitors likely to be taken chronically for hypercholesterolemia, to cross the blood-brain barrier was investigated in normal male volunteers. Lovastatin, which is lipophilic, was detected in cerebrospinal fluid (CSF) at concentrations that may have a pharmacologic effect. Pravastatin, which is hydrophilic, was not detected in CSF. It is concluded that pravastatin may have less potential for causing CNS-related side effects than lovastatin.
在正常男性志愿者中研究了普伐他汀和洛伐他汀(可能长期用于治疗高胆固醇血症的HMG-CoA还原酶抑制剂)穿过血脑屏障的能力。亲脂性的洛伐他汀在脑脊液(CSF)中被检测到,其浓度可能具有药理作用。亲水性的普伐他汀在脑脊液中未被检测到。结论是,与洛伐他汀相比,普伐他汀引起中枢神经系统相关副作用的可能性可能较小。